Another previous case report demonstrated that an advanced NSCLC patient whose EML4-ALK fusion was detected after acquired resistance to osimertinib therapy had a durable response to treatment with the ALK inhibitor ensartinib [43]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.